Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

A Pfizer Covid booster vaccination gave a fit 54-year-old chronic pain, NHS doctors found. Larry Lowe, from Omagh in Northern ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said they will not be involved with activist investor Starboard Value, ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.

Story of activist fund Starboard Value taking $1B position in Pfizer is grabbing headlines the last few days. Read why I ...

All the companies have skin in the game for clotting/bleeding disorders. The BMS-Pfizer Alliance market Factor Xa blood ...

Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting ...